Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma

Part of paid clinical trials in La Jolla, California.

Sponsor
University of California, San Francisco
Study ID
NCT04598009
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Melanoma Stage III
  • Melanoma Stage IV

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Binimetinib — DRUG
    Taken orally (PO) twice a day (BID)
  • Imatinib — DRUG
    Taken orally (PO) once a day (QD)

Study Details

This phase II trial studies how well binimetinib and imatinib work in treating patients with stage III-IV KIT-mutant melanoma that cannot be removed by surgery (unresectable). Binimetinib and imatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving binimetinib and imatinib may help treat patients with KIT-mutant melanoma.

Key Dates

Start date
Mar 3, 2021
Status verified
Jun 2026
Primary completion
May 31, 2027
Completion
May 31, 2028

Study Design

Enrollment
25 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment (binimetinib, imatinib)
    Patients receive binimetinib PO BID on days 1-28 and imatinib PO QD on days 1-28. Cycles repeat every 28 days

Primary Outcome Measure

Objective response rate (ORR) [ Time Frame: Up to week 16 ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
UC San Diego Moores Cancer CenterLa JollaCalifornia92093
Gregory Daniels, MD, PhD
[email protected]
858-534-3804
Gregory Daniels, MD, PhD (PRINCIPAL_INVESTIGATOR)
University of California, San FranciscoSan FranciscoCalifornia94143
Sonia Martinez
[email protected]
415-514-6427
[email protected]
877-827-3222
Katy Tsai, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in La Jolla, CA

By research site
UC San Diego Moores Cancer Center· La Jolla, CAUniversity of California, San Francisco· San Francisco, CA

Related Studies